🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

This work is the result of a remarkable collaboration between **international experts**, and I'm incredibly proud of the insights we’ve brought forward. Grateful to the whole team for their dedication and effort.

Chiara CATANIA We would like to inform you that your post has been published on OncoDaily.com. Thank you for sharing such valuable content. oncodaily.com/blog/chiara-ca…

We Explored Rare Transformations in EGFR-Mutated Lung Cancer - Chiara CATANIA oncodaily.com/blog/chiara-ca… #LungCancer #LCSM #Cancer #OncoDaily #Medicine #Oncology #MedEd #MedX #MedNews CancerWorld

Phase 2 ACHIEVE trial of high-dose aumolertinib for #EGFR NSCLC with brain metastases JAMA Oncology (n=63). RR 88.9%, intracranial RR 82.5%, mPFS 20.5m, 1y PFS rate 62.1%, 1y intracranial PFS rate 76.8%. ctDNA clearance associated with longer PFS. jamanetwork.com/journals/jamao…

Navigating Selective Dose Intensification in EGFR-Variant Non–Small Cell Lung Cancer JAMA Oncology jamanetwork.com/journals/jamao…

Bravo Benjamin Besse! Very welcome news. Looking forward to your Presidency

🚨 #Lungcancer survival has more than doubled. New real-world data from France shows 3-year survival for lung adenocarcinoma rose from 16.3% (2000) to 38.6% (2020) driven by earlier diagnosis & targeted treatment. This is what progress looks like. But it must reach everyone who

A great lecture of Prof. Christian Rolfo at the #Fonicap consensus conference here at the International School of Medical Sciences in Erice 🇮🇹 Thanks for your invaluable contribution and support. International Society of Liquid Biopsy

FDA approval of taletrectinib in #ROS1 NSCLC has immediate impact on patients with this subset of lung cancer. Discussion with Drs. Jorge Nieva and Enriqueta Felip in this episode of the IASLC podcast, Lung Cancer Considered. iaslc.org/iaslc-news/lun…

Correlation between treatments&outcomes of pts with EGFR-mutated NSCLC that transitioned into SCLC: an international retrospective study in ESMO Open. Poor outcomes despite treatment, primary EGFR mutation maintained upon transformation. esmoopen.com/article/S2059-…

Very frequently seen in the age of targeted therapy

Just in time for the new academic year - 50 years of progress in NSCLC in this review article JTO & JTO CRR led by Jarushka Naidoo & the IASLC communications committee. Proud to be part of this effort summarizing profound advances in this lethal disease. jto.org/article/S1556-…

People with #lungcancer & low BMI are more likely to develop brain metastases - a link not seen in other cancers. New open access study in Nature Communications, July 2025. Researchers suggest it’s driven by brain signalling changes, not just weight loss. 🔗

SCLC transformation from EGFR+ NSCLC, outcomes & tx? ESMO Open: - 25pts: CT (n=12), CT+EGFR-TKI (n=5), CT+ICI (n=6), CT+ICI+TKI (n=1) - mPFS 2m; mOS 9m, similar across tx - mOS if transf >12m v <12m (31m vs 8m, p<0.001) Chiara CATANIA OncoAlert #LCSM esmoopen.com/article/S2059-…

Congrats to all authors Stephen V Liu, MD Marina Garassino Federico Cappuzzo Alessandro Russo & more

Update to the ASCO Living Guidelines for NSCLC with driver alterations now Journal of Clinical Oncology from Joshua Reuss et al to include zenocutuzumab for patients with NSCLC that harbors an #NRG1 fusion. ascopubs.org/doi/10.1200/JC…

FLAURA2 press release: addition of chemotherapy to 1L osimertinib in #EGFR NSCLC improves overall survival. Already approved based on significant PFS benefit. Awaiting data to see degree of OS benefit to consider vs MARIPOSA. Important positive update! astrazeneca.com/media-centre/p…

‼️Press release: #FLAURA2 shows osimertinib + chemo improves OS in EGFR+ lung cancer — “statistically significant & clinically meaningful.” Combos may be in, but informed & shared decision-making stays key. Excited to review full data! OncoAlert

#ALK is a viable target even in squamous NSCLC, demonstrated by this case + review in Clinical Lung Cancer. However, significant variability in quality of response. While most respond, many brief courses of crizotinib, one on 1L alectinib for 5y and counting. clinical-lung-cancer.com/article/S1525-…

Available JTO & JTO CRR - the 2024 IASLC Global Survey on Biomarker Testing. Majority (67%) reported most patients had biomarker testing (up from 39% in 2018) but 43% sometimes treated before results. Barriers: cost, time, tissue, access, awareness. jto.org/article/S1556-…